DES has shown success in coronary indications, which has encouraged the development of DES products for peripheral vessels as well. While growing in popularity in Europe, peripheral versions of DES have not been available in the United States. Cook Medicals Zilver PTX is expected to receive Food and Drug Administration (FDA) approval early in 2012. DES will mostly be used initially in femoropopliteal (fem-pop) indications, with use also in the infropopliteal in 2015 and beyond. The overall fem-pop segment had a value of $290 million in 2011 and is expected to reach over $460 million by 2016, a growth rate that averages nearly 10 percent per year.
Drug-eluting stents are expected to address some of the concerns with current stents used in lower-extremity indications, which include restenosis, high rates of re-intervention and durability concerns. The results should be better outcomes in safety and efficacy. As a result, DES in the fem-pop segment should reach 30,000 procedures per year by 2016, making up nearly 7.5 percent of all fem-pop stenting procedures.
"DES is promising, but improvements are constantly being made to its competitors, primarily bare-metal stents, but also including covered stents," said MRG Analyst Fareed Hameed. "Flexible Stenting Solutions and IDEV technologies have new bare-metal designs, while W. L. Gore and Atrium Medical both have made continuous improvements to their covered stents. Physicians need to learn new procedures to use any of these designs effectively, which does decrease the speed of adoption."
Millennium Research Groups US Markets for Peripheral Vascular Devices 2012 report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for PV stents, PTA balloon catheters, atherectomy devices, EPDs, aortic stent grafts, synthetic and biologic surgical stent grafts and PV accessory devices sold in the United States.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
Posted by Sean Fenske, Editor-in-Chief, MDT